Platinum-Taxol non-cross resistance in epithelial ovarian cancer.

The aim of this study was to assess the clinical evidence for platinum-Taxol non-cross-resistance in patients with epithelial ovarian cancer. Unlike other studies, only patients who had demonstrably progressive disease on platinum therapy were analysed. Patients received 135-200 mg m-2 of Taxol over...

Descripción completa

Detalles Bibliográficos
Autores principales: Gore, M. E., Preston, N., A'Hern, R. P., Hill, C., Mitchell, P., Chang, J., Nicolson, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033816/
https://www.ncbi.nlm.nih.gov/pubmed/7779729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033816/
https://www.ncbi.nlm.nih.gov/pubmed/7779729

Ejemplares similares